Preclinical discovery of apixaban, a direct and orally bioavailable factor Xa inhibitor

Executive Summary: Heart Disease and Stroke Statistics—2010 Update

(2010) et al.   CIRCULATION

Clinical burden of venous thromboembolism

(2010) Andras Ruppert et al.   CURRENT MEDICAL RESEARCH AND OPINION

Effect of the Direct Factor Xa Inhibitor Apixaban in Rat Models of Thrombosis and Hemostasis

(2010) William A Schumacher et al.   JOURNAL OF CARDIOVASCULAR PHARMACOLOGY

Factor Xa Inhibitors: Next-Generation Antithrombotic Agents

(2010) Donald J. P. Pinto et al.   JOURNAL OF MEDICINAL CHEMISTRY

Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial

(2010) Michael Rud Lassen et al.   LANCET

Apixaban versus Enoxaparin for Thromboprophylaxis after Hip Replacement

(2010) Michael Rud Lassen et al.   NEW ENGLAND JOURNAL OF MEDICINE

Clinical laboratory measurement of direct factor Xa inhibitors: Anti-Xa assay is preferable to prothrombin time assay

(2010) Zhaoqing Wang et al.   THROMBOSIS AND HAEMOSTASIS

Apixaban, a direct factor Xa inhibitor, inhibits tissue-factor induced human platelet aggregation in vitro: Comparison with direct inhibitors of factor VIIa, XIa and thrombin

(2010) Xiaosui Jiang et al.   THROMBOSIS AND HAEMOSTASIS

Sulfation of O-Demethyl Apixaban: Enzyme Identification and Species Comparison

(2009) L. Wang et al.   DRUG METABOLISM AND DISPOSITION

Comparative Metabolism of 14C-Labeled Apixaban in Mice, Rats, Rabbits, Dogs, and Humans

(2009) D. Zhang et al.   DRUG METABOLISM AND DISPOSITION

In Vitro Assessment of Metabolic Drug-Drug Interaction Potential of Apixaban through Cytochrome P450 Phenotyping, Inhibition, and Induction Studies

(2009) L. Wang et al.   DRUG METABOLISM AND DISPOSITION

Favorable therapeutic index of the direct factor Xa inhibitors, apixaban and rivaroxaban, compared with the thrombin inhibitor dabigatran in rabbits

(2009) P. C. WONG et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Metabolism, pharmacokinetics and pharmacodynamics of the factor Xa inhibitor apixaban in rabbits

(2009) Donglu Zhang et al.   JOURNAL OF THROMBOSIS AND THROMBOLYSIS

Apixaban or Enoxaparin for Thromboprophylaxis after Knee Replacement

(2009) Michael Rud Lassen et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pharmacology and Management of the Vitamin K Antagonists

(2008) Jack Ansell et al.   CHEST

Apixaban Metabolism and Pharmacokinetics after Oral Administration to Humans

(2008) N. Raghavan et al.   DRUG METABOLISM AND DISPOSITION

Arterial antithrombotic and bleeding time effects of apixaban, a direct factor Xa inhibitor, in combination with antiplatelet therapy in rabbits

(2008) P. C. WONG et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Apixaban, an oral, direct and highly selective factor Xa inhibitor:in vitro, antithrombotic and antihemostatic studies

(2008) P. C. WONG et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Efficacy and safety of the oral direct factorXa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study

(2008) et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS